Drug development is a long and costly process that often ends in failure. Improving the way potential drug candidates are optimized could help boost success rates.
Vaccines and medical treatments can only go so far in an unequal society. Facing the ongoing history of racial discrimination and bias in the US would help end the pandemic.
For a number of reasons, as time goes on vaccines become less effective. So how do researchers calculate how well vaccines are working?
Regulatory loopholes for research conducted off US soil allow for questionable trials and misleading data to slip under the FDA’s radar.
While emergency use authorization gets vaccines out to the public more quickly, it doesn’t skip any steps that full approval requires.
Three pioneering technologies have forever altered how researchers do their work and promise to revolutionize medicine, from correcting genetic disorders to treating degenerative brain diseases.
Ongoing tracking is meant to spot very rare risks – like the connection between the Johnson & Johnson shot and Guillain-Barré syndrome. And it relies on public reporting.
As many teens and adults in the US restart their social lives, parents of children under the age of 12 wonder when their kids will also be able to experience the freedom that comes with vaccination.
The FDA approved Alzheimer's disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don't yet have.
UK researchers are launching a clinical trial to investigate if the drug niclosamide, usually used to treat tapeworms, can prevent COVID-19 infection in
/
5
